Observational Study of NovoNorm® in Subjects With Diabetes

NovoNorm Post Marketing Surveillance Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01498913

Enrollment

5841

Registered

2011-12-26

Start date

2001-08-30

Completion date

2005-03-25

Last updated

2017-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.

Interventions

DRUGrepaglinide

Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Type 2 diabetes

Design outcomes

Primary

Measure	Time frame
HbA1c (glycosylated haemoglobin)	—
2 hours postprandial blood glucose (2-hr PPBG)	—
Fasting blood glucose (FBG)	—
Body weight	—

Secondary

Measure	Time frame
Adverse events	—

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026